back to top
HomeMONEYHuge Profit On The First Day; 31% Return In Just 1 Day;...

Huge Profit On The First Day; 31% Return In Just 1 Day; Received Tremendous Response From Investors

Shares of Sharktank judge Namita Thapar’s company Emcure Pharmaceuticals Ltd have been listed on both the exchanges i.e. National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) today.

The special thing is that the shares of this company have been listed at a premium price as compared to the IPO price. 

Along with this, the investors who have been allotted the company’s shares in the subscription process have made great profits on the very first day. The IPO price for Emcure Pharmaceuticals Ltd was fixed at ₹ 1008 per share.

But, compared to this, the stock was listed on NSE at a premium of about 31%. This stock was listed on the NSE at a price of ₹ 1,325 per share.

At the same time, its listing on BSE was listed at a price of ₹ 1,325 per share with a premium of 31%.

Raised ₹ 1952 Crore From IPO

This IPO was open between 3 to 5 July and received a tremendous response from investors. Qualified Institution Buyers (QIBs) have subscribed to this IPO 191 times. 

In this IPO of ₹ 1952.03 crore, 1.37 crore shares were offered for QIBs. Through IP, the pharma company is issuing fresh shares worth ₹ 800 crore. 

Also, there is an offer-for-sale (OFS) of 1.14 crore shares worth ₹ 1,152.03 crore. Through OFS the company’s promoters currently Satish Ramanlal Mishta, Sunil Rajnikant Mehta, Namita Vikas Thapar, and Sameet Satish Mehta will be selling certain shares.

How Much Was Subscribed?

This IPO has been subscribed a total of 67.87 times. Retail category investors have subscribed to it 7.36 times. Whereas, the NII category has received 49.32 times subscription. 

The amount that is reserved for employees has been redeemed 8.81 times. The brokerage had advised to subscribe to the IPO based on a reasonable valuation compared to other listed companies.

16 brokerage firms had advised investors to subscribe to this.

Great Response From Anchor Investors

Before the IPO opened, the company had bought shares worth ₹582.6 crore from anchor investors. The list of anchor investors includes names such as Abu Dhabi Investment Authority, Goldman Sachs, and Morgan Stanley.

In addition, SBI, HDFC, ICICI Prudential, Whiteoak Capital, Aditya Birla Sun Life Trustee, Axis, Kotak, Nippon Life India, Mirae, Franklin India, UTI, Canara Robeco, and Motilal Oswal have also been part of the book anchor.

The lock-in period of 50% for anchor investors is 30 days i.e. till 7 August 2024. Whereas, the entire anchor lock-in period will end after 90 days i.e. on October 6, 2024.

Emcure Pharmaceuticals Ltd Stock Performance

Market Cap₹ 19,061 Cr.
Stock P/E37.9
Book Value
Dividend
ROCE18.6 %
ROE18.5 %
Face Value
P/B Value
OPM18.5 %
EPS₹ 27.5
Debt₹ 2,335 Cr.
Debt to Equity0.79

Emcure Pharmaceuticals Ltd Share: Last 5 Years’ Financial Condition

Last 5 Years’ Sales:

2020₹ 5,049 Cr
2021₹ 5,033 Cr
2022₹ 5,855 Cr
2023₹ 5,986 Cr
2024₹ 6,658 Cr

Last 5 Years’ Net Profit:

2020₹ 101 Cr
2021₹ 419 Cr
2022₹ 703 Cr
2023₹ 562 Cr
2024₹ 528 Cr

Conclusion

This article provides a detail guide about Emcure Pharmaceuticals Ltd share.

The information and forecasts provided result from the analysis of our research team, the company’s basics and history, experience and various technical analyses. 

Also, we’ve talked in depth about the shares’ prospects and growth possibilities.

If you’re new to our site and want to be updated on the latest market information, you can join us on the Telegram Group(Link below).

If you have additional questions, feel free to leave a comment below. We’ll be more than happy to address all of your questions.

Disclaimer: The information on this site is only for informational and educational purposes and shouldn’t be considered financial advice or stock recommendations. 

BEST FOR YOU

LEAVE A REPLY

Please enter your comment!
Please enter your name here